论文部分内容阅读
目的:分析埃克替尼对晚期非小细胞肺癌的治疗效果及对血清指标的影响。方法:将86例晚期非小细胞肺癌患者按抽签法分成对照组与观察组,各43例。对照组采用多西他赛治疗,观察组采用埃克替尼治疗。观察并比较两组患者治疗前后血清细胞角蛋白21-1(Cyfre21-1)、鳞状细胞癌抗原(SCCA)、血管内皮生长因子(VEDF)、自然杀伤(NK)细胞、CD4~+、CD8~+、CD4~+/CD8~+,白细胞介素-8(IL-8)、肿瘤坏死因子-α(TNF-α)、基质金属蛋白酶-2(MMP-2)及基质金属蛋白酶-9(MMP-9)水平、临床疗效以及安全性。结果:观察组疾病控制率高于对照组,差异具有统计学意义(P<0.05)。治疗后,两组患者血清Cyfre21-1、SCCA、CD8~+、LI-8、TNF-α、MMP-2及MMP-9均低于治疗前,且观察组低于对照组,,差异具有统计学意义(P<0.05);治疗后,两组患者血清VEGF水平均降低,且观察组低于对照组,差异具有统计学意义(P<0.05);治疗后,两组患者血清NK、CD4~+及CD4~+/CD8~+均高于治疗前,且观察组高于对照组,差异具有统计学意义(P<0.05);观察组不良反应发生率低于对照组,差异具有统计学意义(P<0.05)。结论:埃克替尼对晚期非小细胞肺癌的临床效果肯定,可下调血清VEGF表达。
Objective: To analyze the therapeutic effect of icotinib on advanced non-small cell lung cancer and its influence on serum indexes. Methods: Eighty-six patients with advanced non-small cell lung cancer were divided into control group and observation group according to random sampling method, 43 cases in each group. The control group received docetaxel treatment, the observation group used imatinib treatment. The levels of serum cytokinin 21-1, SCCA, VEDF, NK cells, CD4 ~ +, CD8 CD4 ~ + / CD8 ~ +, IL-8, TNF-α, MMP-2 and MMP- MMP-9) levels, clinical efficacy and safety. Results: The disease control rate in the observation group was higher than that in the control group, with significant difference (P <0.05). After treatment, the serum levels of Cyfre21-1, SCCA, CD8 +, LI-8, TNF-α, MMP-2 and MMP-9 in both groups were lower than those before treatment, and the difference between the two groups was statistically significant (P <0.05). After treatment, serum VEGF levels decreased in both groups, and the observation group was lower than the control group, the difference was statistically significant (P <0.05); After treatment, serum NK, CD4 ~ + And CD4 ~ + / CD8 ~ + were higher than before treatment, and the observation group was higher than the control group, the difference was statistically significant (P <0.05); adverse reaction rate in the observation group was lower than that in the control group, the difference was statistically significant (P <0.05). Conclusion: Icitinib has a positive clinical effect on advanced non-small cell lung cancer and can downregulate serum VEGF expression.